Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.
Bruno FrancoisXavier WitteboleRicard FerrerJean-Paul MiraThierry DugernierSébastien GibotMarc DeriveAurélie OlivierValérie CuvierStephan WittePeter PickkersFrançois VandenhendeJean-Jacques GaraudMiguel SánchezMargarita Salcedo-MagguilliPierre-François LaterrePublished in: Intensive care medicine (2020)
No significant increases in TEAEs were detected in nangibotide-treated patients versus placebo. These results encourage further evaluation of nangibotide and further exploration of plasma sTREM-1 concentrations as a predictive efficacy biomarker.